It is now recognized that beyond cholesterol storage issues, cardiac inflammation plays a critical role in the development and progression of atherosclerotic cardiovascular disease (ASCVD). In June 2023, the U.S. Food and Drug Administration approved the first anti-inflammatory cardiovascular treatment, indicating a reduction of myocardial infarction, stroke, coronary revascularization and cardiovascular death in adult patients with established ASCVD or multiple risk factors. The expert speaker will share his perspective on the opportunities with these new clinical developments.

John G. Canto, MD, MSPH, FACC, FACP, FAHA, FASE
Cardiologist, Invasive Noninterventional Cardiology Director
CV Prevention, Research & Education Watson Clinic Lakeland